Benefit vs potential harm of genome-wide prenatal cfDNA testing requires further investigation and should not be dismissed based on current data
Ultrasound Obstet Gynecol
.
2020 May;55(5):695-696.
doi: 10.1002/uog.22030.
Authors
M N Bekker
1
,
L Henneman
2
,
M V E Macville
3
,
E A Sistermans
2
,
R J H Galjaard
4
Affiliations
1
Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
2
Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
3
Department of Clinical Genetics, Maastricht UMC+, Maastricht, The Netherlands.
4
Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.
PMID:
32356934
DOI:
10.1002/uog.22030
No abstract available
Publication types
Letter
Comment
MeSH terms
Cell-Free Nucleic Acids*
Female
Humans
Pregnancy
Prenatal Diagnosis
Substances
Cell-Free Nucleic Acids
Grants and funding
No. 543002001/ZONMW_/ZonMw/Netherlands